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Summary
EGF receptor (EGFR) overexpression correlates with metastasis in a variety of carcinomas, but the underlying mechanisms
are poorly understood. We demonstrated that EGF disrupted cell-cell adhesion and caused epithelial-to-mesenchymal
transition (EMT) in human tumor cells overexpressing EGFR, and also induced caveolin-dependent endocytosis of
E-cadherin, a cell-cell adhesion protein. Chronic EGF treatment resulted in transcriptional downregulation of caveolin-1
and induction of the transcriptional repressor Snail, correlating with downregulation of E-cadherin expression. Caveolin-1
downregulation enhanced -catenin-TCF/LEF-1 transcriptional activity in a GSK-3-independent manner. Antisense RNA-
mediated reduction of caveolin-1 expression in EGFR-overexpressing tumor cells recapitulated these EGF-induced effects
and enhanced invasion into collagen gels. We propose that EGF-induced negative regulation of caveolin-1 plays a central
role in the complex cellular changes leading to metastasis.
Introduction but also the disruption of cell-cell junctions. The stimulation of
epithelial cells with growth factors, such as hepatocyte growth
Epidermal growth factor (EGF) receptor overexpression has factor/scatter factor (HGF/SF) (Muller et al., 2002; Savagner et
been reported in many human tumors, including lung, colon, al., 1997; Weidner et al., 1990), FGF (Shtutman et al., 1999;
breast, prostate, brain, head and neck, thyroid, ovarian, bladder, Valles et al., 1990), EGF (Blay and Brown, 1985; Geimer and
gliomas, and renal carcinoma (Berger et al., 1987; Gullick, 1991; Bade, 1991; Muller et al., 2002), and TGF- (Miettinen et al.,
Lemoine et al., 1991; Libermann et al., 1985; Salomon et al., 1994), induces break-up of cell-cell junctions. The disruption
1995; Tillotson and Rose, 1991). EGF receptor (EGFR) overex- of cell-cell junctions facilitates EMT and tumor cell migration
pression correlates with poor clinical prognosis in tumors and is (Birchmeier et al., 1995; Hay and Zuk, 1995). EMT can result
often accompanied by production of TGF- or other EGF family
from multiple extracellular stimuli; for instance, a synergistic
ligands (Voldborg et al., 1997). Autocrine regulation through
effect on EMT has been observed with combined stimulationEGFR by such ligands contributes to tumor progression.
of EGF and TGF- (Grande et al., 2002).EGF promotes tumor cell motility and invasion (Price et al.,
A major component of the epithelial adherens junction is1996; Rosen and Goldberg, 1989; Shibata et al., 1996). Re-
E-cadherin. E-cadherin is a member of a family of functionallycently, we showed that EGF-induced dephosphorylation and
related transmembrane glycoproteins that mediate Ca2-inactivation of FAK leads to cell detachment, increased motility,
dependent cell-cell adhesion via homophilic interaction withand invasion, followed by integrin-dependent FAK reactivation
adjacent cells through their N-terminal ectodomains. The cyto-during re-adhesion (Lu et al., 2001b). This dynamic regulation
plasmic C-terminal domain of E-cadherin directly interacts withof FAK activity plays a role in EGF-associated tumor invasion
/-catenin (or plakoglobin). -catenin binds -catenin, whichand metastasis (Lu et al., 2001b). Tumor cell migration and
in turn binds to vinculin, -actinin, ZO-1, and F-actin, and thusmetastasis is a highly coordinated process involving not only
alteration of cell adhesion to extracellular matrix (ECM) proteins, links E-cadherin to the actin cytoskeleton (Nagafuchi, 2001;
S I G N I F I C A N C E
EGF-induced signaling, downregulation of E-cadherin, and increased -catenin have been reported separately to correlate with
the invasive stage of tumor development. However, the exact relationship between them is not clear. We present data showing that
endocytosis of E-cadherin and downregulation of caveolin-1 itself induced by EGF signaling result in depletion of E-cadherin protein,
disruption of cell-cell contacts, and GSK-3-independent -catenin-TCF/LEF-1 transactivation. All these events contribute to invasive
tumor development. This interplay between EGF and Wnt/Wingless signaling components provides an important mechanism for
understanding tumor cell invasion and metastasis.
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Rimm et al., 1995; Vasioukhin and Fuchs, 2001). Regulation of served in several other types of cancers, including colon cancer,
E-cadherin-mediated cell-cell adhesion by different mecha- melanoma, and prostate cancer (Morin, 1999; Peifer and Po-
nisms alters the dynamics of cell-cell junction formation and lakis, 2000). However, the dynamic regulation of -catenin
maintenance (Gumbiner, 2000). For instance, E-cadherin inter- protein levels by exchange of molecules between the spatially
nalization in response to HGF is accompanied by the disruption separated pools that function in cell-cell adhesion and in trans-
of cell-cell adhesion and scattering of cells (Kamei et al., 1999). activation in the context of tumor cell invasion and metastasis
The critical role of E-cadherin-mediated cell-cell adhesion in is less well understood (Papkoff, 1997). Disruption of adherens
metastasis is exemplified by the fact that the development of junctions releases -catenin from the adherens junction com-
invasive tumors often correlates with the downregulation of plex, thus making it available for nuclear import and increased
E-cadherin expression (Berger et al., 1987). Moreover, inactivat- transactivation of -catenin-responsive genes. In colorectal tu-
ing mutations in the E-cadherin gene, consisting of splice site
mors, dissociated cells at the invasive front that have lostmutations and truncation mutations caused by insertions, dele-
E-cadherin expression show nuclearly localized -catenin (Bra-tions, and nonsense mutations, have been found in gastric,
bletz et al., 2001). c-Fos and IGF-2 induce nuclear translocationcolon, and breast cancer (Berx et al., 1998; Efstathiou et al.,
and transactivation of -catenin during EMT (Eger et al., 2000;1999; Guilford et al., 1998; Salahshor et al., 2001). Loss of
Morali et al., 2001), whereas Vitamin D3 promotes differentiationE-cadherin expression has been demonstrated as a causal fac-
of colon carcinoma cells by induction of E-cadherin expressiontor for tumor progression in a transgenic mouse model of pan-
and the translocation of -catenin to the plasma membranecreatic -cell carcinoma (Perl et al., 1998). Restored expression
(Palmer et al., 2001). Paradoxically, the regulation of -cateninof E-cadherin enhances intercellular adhesion, inhibits tumori-
transcriptional activity by E-cadherin appears to be independentgenicity, and suppresses the invasiveness of epithelial tumor
cells (Efstathiou et al., 1999; Frixen et al., 1991; Vleminckx et of the cell-cell adhesion domain of E-cadherin (Gottardi et al.,
al., 1991). 2001) and may function in a cell adhesion-independent manner
Other components of the adherens junction, like - and (Gottardi et al., 2001; Stockinger et al., 2001).
-catenins, also play an important role in tumor progression. Although cadherins and catenins constitute the major struc-
Loss of -catenin compromises intercellular adhesion and re- tural components of cell adherens junctions, the ultrastructure
sults in hyperproliferation of epidermal cells (Vasioukhin et al., of the plasma membrane itself is critical for the organization
2001). In addition to its role in cell-cell adherens junctions, of adherens junctions. Discrete microdomains in the plasma
-catenin is also a key component of the Wnt/Wingless signal membrane, such as caveolae and lipid rafts, serve to target,
transduction cascade. Wnt signaling plays a central role in de- traffic, and/or anchor proteins to their specific subcellular sites
velopment, cell proliferation, and differentiation (Cox et al., 1996;
of action. Caveolae, 50–100 nm protein-coated invaginations
Huelsken et al., 2000; Wodarz and Nusse, 1998). In the absence
of the plasma membrane, play an important role in endocytosisof a Wnt/Wingless signal, cytoplasmic -catenin interacts with
and signal transduction (Anderson, 1998; Galbiati et al., 2001).axin/conductin, glycogen synthase kinase-3 (GSK-3), and the
Caveolin-1, a principal component of caveolar membrane coat,adenomatous polyposis coli protein (APC), which competes
is expressed as  and  isoforms, which have overlapping butwith E-cadherin for binding to the armadillo-like (ARM) repeats
slightly different distributions in mammalian cells (Scherer et al.,of -catenin (Hulsken et al., 1994). -catenin is phosphorylated
1995). EGFR, platelet-derived growth factor receptor (PDGFR),in its N-terminal domain by GSK-3, which leads to its degrada-
Neu/ErbB2, Ha-Ras, c-Src, endothelial nitric oxide synthasetion mediated by the SCF/ubiquitin/proteasome pathway (Ab-
(eNOS), and phosphatidylinositol 3-kinase are known to localizeerle et al., 1997; Behrens et al., 1998; Ikeda et al., 1998; Orford
et al., 1999; Rubinfeld et al., 1996; Yost et al., 1996). Activation in caveolae and are negatively regulated through their interac-
of the Wnt/Wingless pathway inhibits GSK-3-dependent phos- tion with the caveolin-1 scaffolding domain (Garcia-Cardena et
phorylation of -catenin. Stabilized, hypophosphorylated -cate- al., 1997; Okamoto et al., 1998). Caveolin-1 mRNA and protein
nin translocates to the nucleus, where it interacts with transcrip- expression levels are both downregulated during cell transfor-
tion factors of the TCF/LEF-1 family, leading to increased mation by oncogenic Ha-Ras, v-Abl, Myc, Neu, and other onco-
expression of genes, such as c-myc and cyclin D1 (He et al., proteins (Koleske et al., 1995; Okamoto et al., 1998). Moreover,
1998; Shtutman et al., 1999; Tetsu and McCormick, 1999). HGF reduced caveolin-1 protein levels are also observed in a number
and EGF induce -catenin signaling under conditions where of human cancers (Bagnoli et al., 2000; Bender et al., 2000;
they stimulate cell motility (Muller et al., 2002). Gain-of-function Racine et al., 1999; Razani et al., 2001b; Wiechen et al., 2001),
mutations in -catenin, including N-terminal mutations that lead
suggesting a negatively regulatory role for caveolin-1 in tumor
to stabilization of the protein, or loss-of-function mutations in
development. Consistent with these observations, the prolifera-proteins that participate in the regulated turnover of -catenin,
tion rate of caveolin-1-deficient cells is significantly increasedsuch as the tumor suppressor APC, all result in upregulation
(Drab et al., 2001; Razani et al., 2001a).of -catenin protein levels, thus increasing its transcriptional
In this report, we extend our studies on the mechanisms ofactivity. Transgenic mice expressing an activated -catenin un-
EGF-induced tumor cell invasion and metastasis and examineder control of the keratin 14 promoter are predisposed to devel-
the effect of EGFR activation on interactions between caveolin-1oping skin tumors resembling pilomatricomas (Gat et al., 1998).
and cell-cell adhesion components. We demonstrate that EGFMore than 75% of human pilomatricomas possess -catenin-
treatment leads to negative regulation of caveolin-1, which re-stabilizing mutations in CTNNB1 (which encodes -catenin)
sults in downregulation of E-cadherin and disassembly of cell-(Chan et al., 1999).
cell contacts, increased transcriptional activity of -catenin, andIncreased -catenin-TCF/LEF-1 transactivation, resulting
from mutations in APC, axin, or -catenin, has been also ob- enhanced invasion by tumor cells.
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Results EGF-induced internalization of E-cadherin (Figure 1D). Thus,
EGF-induced loss of E-cadherin from cell-cell contacts is not
mediated through a clathrin-dependent endocytotic mecha-EGF treatment results in disruption of cell-cell
contacts, EMT, and caveolae-dependent endocytosis nism.
Caveolar uptake provides an alternative internalization mecha-of E-cadherin in tumor cells that overexpress EGFR
The development of invasive tumors often correlates with the nism to clathrin-mediated endocytosis, and caveolae have been
shown to be involved in the cellular transport of albumin (Razanidownregulation of E-cadherin, and EGFR overexpression is fre-
quently associated with poor clinical prognosis. Therefore, we et al., 2001a), pathogens (Pelkmans et al., 2001), cholesterol
(Smart et al., 1996), endothelin receptor type 1 (Okamoto et al.,investigated the relationship between E-cadherin-mediated
cell-cell contacts and EGF-dependent signaling mechanisms in 2000), and growth hormone (Lobie et al., 1999) into cells. In
addition, EGF triggers caveolin-1 redistribution from the plasmaA431 human epidermoid carcinoma cells, which overexpress
EGFR. Cells were treated with EGF (100 ng/ml) for different membrane to the early/sorting endocytotic compartment of he-
patocytes (Pol et al., 2000). To test whether there is an interac-periods of time. After short periods of EGF treatment (30 min),
these cells exhibited a rounded and refractile morphology ac- tion between E-cadherin and caveolin-1, reciprocal immunopre-
cipitation experiments using anti-E-cadherin or anti-caveolin-1companied by alteration of cell-cell contacts. One day after EGF
treatment, the cells began to grow on top of each other and antibodies were undertaken and revealed that the proteins asso-
ciated with each other in the absence of EGF treatment (Figurebecame elongated and spindle-shaped, resembling the mor-
phology of mesenchymal cells (Figure 1A, left panel). To investi- 1E). The association was still detected at 1 hr of EGF treatment,
but gradually dissipated after prolonged EGF treatment (Figuregate if the EGF-induced disruption of cell-cell contacts and EMT
is restricted to A431 cells or represents a more generalized 1E). Consistent with this, costaining with anti-caveolin-1 and
anti-E-cadherin antibodies displayed partial colocalization ofresponse of EGFR-overexpressing tumor cell lines, A549 human
non-small lung cancer cells and DU145 human prostate cancer both proteins at cell-cell contacts in untreated cells and in an
intracellular compartment after 2 hr of EGF treatment (Figurecells, which also overexpress EGFR, were treated with EGF for
5 days. These cells also exhibited phenotypic changes upon 1F). A fraction of total caveolin-1 and E-cadherin was recycled
and colocalized at the cell membrane after 24 hr of EGF stimula-EGF treatment (Figure 1A, middle panels), similar to those ob-
served for the A431 cells. Consistent with EMT, we observed tion. Treatment of cells with the cholesterol-sequestering re-
agent filipin, which is known to disrupt cholesterol-rich caveolaean increase in expression of vimentin, which is a marker of
mesenchymal cells (Tsarfaty et al., 1994), along with a concomi- (Ros-Baro et al., 2001; Torgersen et al., 2001), blocked endocy-
tosis of E-cadherin (Figure 1G) as well as albumin uptake buttant decrease in expression of an epithelial protein cytokeratin
in DU145 cells after EGF treatment for 5 days (Figure 1A, right not internalization of transferrin (data not shown). Identical re-
sults were obtained with -cyclodextrin, another cholesterol-panel).
Since treatment of A431 cells with EGF resulted in disruption sequestering reagent (data not shown). These data suggest
that E-cadherin is endocytosed from the cell-cell contacts byof cell-cell contacts, we investigated the effect of EGF treatment
on cellular E-cadherin localization. E-cadherin was concen- a clathrin-independent pathway and that EGF-induced E-cadh-
erin endocytosis may involve a caveolae-dependent mech-trated near the apical surface at cell-cell contacts, indicative of
the existence of E-cadherin-mediated interactions in these cells, anism.
although these cells do not form true tight junctions, as demon-
strated by the absence of ZO-1 in cell-cell contacts (data not Chronic EGF treatment downregulates protein
expression of caveolin-1 and E-cadherinshown). Immunofluorescence staining experiments revealed
that 2 hr of EGF treatment resulted in internalization of E-cadh- at the transcriptional level
Short-term EGF treatment disrupted cell-cell contacts, whereaserin protein from the cell-cell contacts in A431 cells (Figure
1B), suggesting that E-cadherin is endocytosed following EGF prolonged treatment not only prevented cells from contacting
each other but also caused EMT. To investigate the basis fortreatment. Similar results were obtained with human A549 lung
cancer and rat NBT-II bladder carcinoma cells (Figure 1B). Fur- these long-term effects of EGF, we tested the effect of chronic
EGF treatment on expression levels of caveolin-1 and the cellthermore, EGF-induced internalized E-cadherin colocalized with
the Golgi marker -COP, a subunit of the COP1 endoplasmic adherens junction proteins E-cadherin,-catenin, and-catenin
in A431 cells. Immunoblotting analyses revealed that the levelsreticulum (ER)-Golgi apparatus transport system (Marsh and
McMahon, 1999). This indicates that E-cadherin translocates of caveolin-1 and E-cadherin proteins were dramatically re-
duced at 3 days of EGF treatment and became undetectableto a compartment that partially overlaps with the Golgi upon
EGF treatment. after 5 days of treatment (Figure 2A). In contrast to caveolin-1
and E-cadherin, there were only modest reductions in the levelsTo investigate the mechanism of EGF-induced E-cadherin
internalization, GFP-tagged Eps15 95-295, which lacks the of -catenin and -catenin (Figure 2A) and the focal adhesion
protein FAK (data not shown), and the levels of the ERK1/2second and third EH (Eps15 Homology) domains, was tran-
siently transfected into A431 cells. Eps15 associates with com- MAP kinases (Figure 2A) were unaffected. EGF treatment of
A549 and DU145 cells also caused downregulation of caveolin-1ponents of clathrin-mediated endocytotic machinery, such as
Epsin, through its EH domains, and plays a role in assembly of and E-cadherin proteins (Figure 2A). The removal of EGF for 3
days resulted in the restoration of expression of both caveolin-1clathrin-coated pits (CCP) (Marsh and McMahon, 1999). The
Eps15 95-295 mutant lacking EH domains inhibits CCP as- and E-cadherin with similar kinetics (Figure 2B).
To determine whether EGF-induced downregulation ofsembly (Benmerah et al., 1999, 2000) and inhibited clathrin-
dependent endocytosis of transferrin in A431 cells (Figure 1D). E-cadherin and caveolin-1 was regulated at the posttransla-
tional level, a pulse-chase analysis was carried out followingHowever, the expression of Eps15 95-295 did not prevent
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Figure 1. EGF treatment results in disruption of cell-cell junctions, EMT, and caveolae-dependent endocytosis of E-cadherin in tumor cells that overexpress
EGFR
A: A431 (upper panel) and A549 and DU145 (middle panel) cells were treated with EGF (100 ng/ml) for the indicated times, and morphological changes
were observed by phase-contrast microscopy. The expression of vimentin and cytokeratin in DU145 cells treated with or without EGF (100 ng/ml) for 5 days
was assessed by immunoblotting analysis (right panel).
B: Deconvolution microscope images of E-cadherin (green) and actin stained with TRITC-labeled phalloidin (red) in A431 cells (upper panel) untreated or
treated with EGF (100 ng/ml) for 2 hr; yellow indicates the staining overlap. E-cadherin staining (green) in A549 cells (middle panel) and NBT-II cells (lower
panel) untreated or treated with EGF.
C: A431 cells treated with EGF for 2 hr were immunostained with anti-E-cadherin (red) and anti--COP (green) antibodies.
D: A431cells were transiently transfected with GFP-tagged Eps15 95-295 followed by EGF (100 ng/ml) treatment for 2 hr and incubated with Alexa Fluor
594-conjugated transferrin (5 g/ml) (red) for 30 min. E-cadherin, stained with mouse anti-E-cadherin antibody followed by Cy-5-conjugated anti-mouse
antibody, is represented by pseudo-blue color.
E: Immunoprecipitation of E-cadherin from cells that were untreated or treated with EGF (100 ng/ml) for the indicated times was followed by immunoblotting
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Figure 2. Chronic EGF treatment downregulates
expression of caveolin-1 and E-cadherin proteins
at the transcriptional level
A: The expression levels of caveolin-1, E-cadh-
erin, -catenin, -catenin, ERK1/2, and FAK in
A431 (left panel) or caveolin-1 and E-cadherin
in DU145 cells and A549 cells (right panel) were
assessed by immunoblotting with indicated anti-
bodies.
B: A431 cells were either untreated or treated
with EGF for 3 days or with removal of EGF for 3
days after EGF treatment for 3 days. The cell ly-
sates were assessed by immunoblotting with the
indicated antibodies.
C: A431 cells treated with EGF (100 ng/ml) for 3
days were labeled with [35S]methionine for 1 hr
and pulse-chased for the indicated time in the
presence or absence of EGF treatment. Caveo-
lin-1 or E-cadherin was immunoprecipitated, an-
alyzed by SDS-PAGE, and transferred to nitrocel-
lulose membranes for autoradiography.
D: Northern blot analyses for caveolin-1 (upper
panel), E-cadherin (second panel), -catenin
(third panel), and -actin (lower panel) for A431
cells treated with or without EGF (100 ng/ml) for
5 days.
E and F: 293T cells were transiently transfected
with pEGFR expression vector and pA3Luc-cave-
olin-1 (E) or pGL 3-E-cad (178/92) vector
containing the luciferase (Luc) gene under the
control of the178/ 92 fragment of the human
E-cadherin promoter (F). Cells were either left
untreated or treated with EGF (100 ng/ml) for 12
hr before harvesting. Cell extracts were pro-
cessed for measurement of luciferase activity.
Data represent the mean 	 standard deviation
of 3 independent experiments.
chronic EGF treatment for 3 days and in untreated control cells; caveolin-1 and E-cadherin expression at the transcriptional
level.EGF treatment caused no major change in the half-life of either
caveolin-1 or E-cadherin protein (Figure 2C). To determine
whether the decrease in protein was due instead to a change EGF treatment induces -catenin dissociation from
in mRNA levels, Northern blotting analysis was carried out after E-cadherin, translocation to the nucleus, and increased
5 days of EGF treatment. The levels of both E-cadherin and transactivation by GSK-3-independent mechanisms
caveolin-1 mRNAs were dramatically reduced, whereas -cate- -catenin associates with E-cadherin at cell-cell junctions.
nin mRNA levels exhibited little change in these cells when Therefore, the internalization of E-cadherin and the disruption
compared to the -actin mRNA control (Figure 2D). Additionally, of cell-cell junctions in response to EGF treatment might result
EGF treatment suppressed the promoter activity of both caveo- in the redistribution of membrane-localized -catenin. To test
lin-1 and E-cadherin in reporter gene assays in which 293T cells this, E-cadherin was immunoprecipitated followed by immu-
were transiently cotransfected with pEGFR expression vector noblotting with anti--catenin antibody. The level of E-cadherin-
associated -catenin was reduced after short periods of EGFand either a caveolin-1 promoter- (Engelman et al., 1999; Park
et al., 2001) or E-cadherin promoter-luciferase reporter (Figures treatment (1 hr) and showed70% reduction after 1 day (Figure
3A). Relatively similar amounts of E-cadherin protein were de-2E and 2F; Poser et al., 2001). These data suggest that chronic
EGF treatment of A431 cells causes downregulation of both tected in the immunoprecipitates, in contrast to the reduced
with anti-caveolin-1 antibody (upper panel). The blot was reprobed with anti-E-cadherin antibody (second panel). Reverse immunoprecipitation with anti-
caveolin-1 antibody was followed by immunoblotting with anti-E-cadherin antibody (third panel). The blot was reprobed with anti-caveolin-1 antibody
(bottom panel).
F: Deconvolution microscope images for E-cadherin (red) and caveolin-1 (green) in A431 cells treated with or without EGF (100 ng/ml) for indicated time.
G: Deconvolution microscope images for E-cadherin (green) in A431 cells either untreated or treated with EGF (100 ng/ml) alone for 2 hr or followed by
30 min of filipin (5 g/ml) or methyl--cyclodextrin (5 mM) treatment.
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Figure 3. EGF treatment induces -catenin dissociation from E-cadherin, translocation to the nucleus, and increased transactivation by GSK-3-independent
mechanisms
A: Immunoprecipitated E-cadherin from A431 cells untreated or treated with EGF (100 ng/ml) for the indicated times were analyzed by SDS-PAGE and
immunoblotted with anti--catenin antibody (upper panel). The blot was reprobed with E-cadherin antibody (lower panel).
B: Deconvolution microscopy for -catenin (green) and Hoechst 33342-stained nuclei (blue) in A431 cells either untreated or treated with EGF (100 ng/ml)
for 1 hr.
C: Nuclear fractions of A431 cells were processed for immunoblotting with anti--catenin or PCNA antibody.
D: Northern blot analyses for c-Myc and -actin (left panel) and immunoblotting for c-Myc and -tubulin (right panel) in A431 cells treated with or without
EGF (100 ng/ml) for 1 day were carried out.
E: FOP-FLASH or TOP-FLASH plasmids with pEGFR were transiently transfected into 293T cells. Cells were either untreated or treated with EGF (100 ng/ml) for
12 hr before harvesting. Cell extracts were measured for lucifererase activity. Data represent the mean 	 standard deviation of 3 independent experiments.
F: FOP-FLASH or TOP-FLASH plasmids with pEGFR were transiently transfected with vectors expressing wild-type -catenin or -Eng into 293T cells. Luciferase
assay was carried out on the lysates prepared from these cells.
G: The level of GSK-3-phosphorylated -catenin in A431 cells in the presence or absence of EGF (100 ng/ml) for the indicated time or calyculin A (50 nM)
for 1 hr was examined by analyzing cell lysates by SDS-PAGE, immunoblotting with phospho--catenin (S33/S37/T41)-specific antibody, and then reprobing
with anti--catenin antibody.
level of total E-cadherin observed by immunoblotting whole-cell clear preparations were free of cytosolic contaminants (data not
shown). Consistently, we also observed that EGF treatmentprotein (Figure 2A). This is because the amount of E-cadherin
increased the levels of both c-myc mRNA and c-Myc protein,antibodies used for the immunoprecipitation was limiting and
a downstream target gene for -catenin transactivation (Figurethe antibodies were saturated with E-cadherin. Immunofluo-
3D). To examine the effect of EGF on the transcriptional activityrescence staining analyses with -catenin-specific antibodies
of TCF/LEF-1, which is activated after binding -catenin, thealso revealed reduced -catenin staining at cell membrane follow-
TCF/LEF-1 luciferase reporter TOP-FLASH or a control vectoring EGF treatment for 2 hr, in contrast to untreated controls in
FOP-FLASH was cotransfected with a vector expressing EGFRwhich -catenin was primarily restricted to the cell-cell contacts
into 293T cells. Upon EGF treatment for 6 hr, there was a signifi-(Figure 3B). Thus, -catenin dissociates from E-cadherin and is
cant increase in TCF/LEF-1 transcriptional activity (Figure 3E).
internalized from cell-cell contacts in response to EGF treatment. In contrast to wild-type -catenin, -Engrailed (-Eng), in which
To test whether -catenin released from E-cadherin accu- the C-terminal transactivation domain of -catenin is replaced
mulates in the nucleus following EGF treatment and interacts with the transcriptional repression domain of Drosophila En-
with transcription factors of the TCF/LEF-1 family, nuclei were grailed (Montross et al., 2000), failed to enhance TCF/LEF-1
isolated from A431 cells. Immunoblotting experiments detected transcriptional activity after EGF treatment in this system (Figure
an increase in nuclearly localized -catenin following 6 hr of 3F). This indicates that EGF induces -catenin-dependent TCF/
EGF treatment, whereas the amount of the nuclear protein PCNA LEF-1 activation. Thus, in response to EGF treatment, -catenin
remained unchanged (Figure 3C). Moreover, we did not detect dissociates from cell-cell contacts, accumulates in the nucleus,
and promotes TCF/LEF-1 transcriptional activity.any E-cadherin in the nuclear fractions, indicating that the nu-
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-catenin protein and transactivation activity can be upregu- whereas expression of antisense caveolin-1 RNA by itself en-
hanced Snail transcription, and a further increase was observedlated by inhibition of N-terminal phosphorylation by GSK-3.
However, in contrast to the significant increase of -catenin with EGF stimulation (Figure 4F). These data indicate that down-
regulation of caveolin-1 is necessary and sufficient for EGF-phosphorylation induced by a phosphatase inhibitor, calyculin
A, we did not detect any dramatic change in GSK-3-dependent induced upregulation of Snail. EGF-induced Snail transcription,
which is regulated by downregulation of caveolin-1, plays an-catenin phosphorylation in response to EGF stimulation using
a phospho--catenin (S33/S37/T41)-specific antibody (Figure important role in transcriptional downregulation of E-cadherin.
3G). Moreover, there was no significant change in the level of
phosphorylated GSK-3 in response to EGF as determined us- Downregulation of caveolin-1 is necessary
and sufficient for EGF-induced -catenining a phospho-GSK-3 (S9)-specific antibody (data not shown).
These data indicate that EGF-stimulated -catenin transactiva- transcriptional activity
Caveolin-1-mediated endocytosis and downregulation oftion is not mediated by GSK-3 inactivation.
E-cadherin may lead to the disassembly of the E-cadherin/
-catenin complex and contribute to the release of -cateninDownregulation of caveolin-1 is sufficient for the
upregulation of Snail and downregulation of E-cadherin from its membrane anchor and thereby allow transactivation.
To test this, 293T cells were transiently transfected with theCaveolin-1 is downregulated in a number of cell types when
transformed by different oncoproteins. Therefore, we next ex- TOP-FLASH reporter and an EGFR expression vector, and with
antisense or wild-type caveolin-1 expression vector. The ex-amined whether there is a direct causal relationship between
the downregulation of caveolin-1 and E-cadherin. A431 cells pression of antisense caveolin-1 RNA in the absence of EGF
significantly enhanced -catenin-TCF/LEF-1 transcriptional ac-stably transfected with a vector that expresses antisense caveo-
lin-1 RNA (Nasu et al., 1998) exhibited reduced expression of tivity as quantified by the luciferase assays. Conversely, the
expression of wild-type caveolin-1 dramatically inhibited bothendogenous caveolin-1 (Figure 4A). Moreover, the expression
level of E-cadherin, but not ERK1/2, was also significantly re- basal and EGF-induced LEF-1 transcriptional activity (Figure 5).
These data indicate that the downregulation of caveolin-1 isduced in these cells (Figure 4A). The residual levels of caveolin-1
and E-cadherin in A431 cells expressing antisense caveolin-1 necessary and sufficient for EGF-induced -catenin transcrip-
tional activity.RNA remained sensitive to long-term EGF treatment and
showed a further decrease over 5 days (Figure 4A).
To determine whether E-cadherin downregulation induced The effects of EGF autocrine regulation on cell
morphology and the expression levelsby expression of antisense caveolin-1 RNA is regulated at the
mRNA level as it is by EGF treatment, E-cadherin mRNA levels of caveolin-1 and E-cadherin
EGFR overexpression is often accompanied by tumor cell pro-were analyzed by Northern blotting. Although -catenin mRNA
levels remained unchanged, as did -actin mRNA, E-cadherin duction of TGF- or other EGF family ligands, and autocrine
regulation via EGF family ligands has been implicated in tumormRNA levels showed a dramatic reduction in the cells express-
ing antisense-caveolin-1 RNA (Figure 4B), compared to the progression (Ethier et al., 1996; Kumar and Mendelsohn, 1990;
Ma et al., 1998; Tillotson and Rose, 1991). To test the effectparental cells. These data indicate that downregulation of cav-
eolin-1 through expression of antisense caveolin-1 RNA recapit- of autocrine regulation on caveolin-1 and E-cadherin cell-cell
adherens proteins, A431 cells were grown for 7 days in theulates the effect of EGF and is sufficient for downregulation of
both E-cadherin mRNA and protein expression. absence or presence of AG1478 (300 nM). AG1478, an EGFR
inhibitor, interrupts the autocrine regulation loop by inhibitingTo explore the mechanism of EGF-induced transcriptional
downregulation of E-cadherin, we next examined the effect of EGFR activation. As shown in Figure 6A, A431 cells treated
with AG1478 became flatter and larger, formed tight cell-cellEGF on Snail expression, since Snail, Slug, and SIP1 family
transcription factors have been shown to bind to the E boxes adhesions, and grew in a monolayer, thus recapitulating the
phenotypes of nontransformed cells. Consistent with the tightin the E-cadherin promoter, repress transcription of E-cadherin,
and induce EMT and invasion (Batlle et al., 2000; Cano et al., cell-cell contacts formed by cells treated with AG1478, the ex-
pression of caveolin-1 and E-cadherin, but not of FAK, was2000; Comijn et al., 2001; Savagner et al., 1997). Snail mRNA
levels measured by RT-PCR were increased significantly in re- substantially increased in these cells (Figure 6B). These data
imply that EGFR autocrine regulation in tumors plays a criticalsponse to EGF treatment (Figure 4C). Consistently, A431 cells
expressing caveolin-1 antisense RNA contained an elevated role in the downregulation of caveolin-1 and E-cadherin, which
in turn contribute to disruption of cell-cell contacts, EMT, andlevel of Snail mRNA, similar to that in EGF-treated cells. Addi-
tionally, expression of Snail siRNA using the pRETRO-SUPER tumor progression.
(pRS) vector, which reduced endogenous Snail mRNA levels
in 293T cells (Figure 4D), increased the promoter activity of Downregulation of caveolin-1 is sufficient
for EGF-induced cell invasionE-cadherin and inhibited EGF-induced suppression of its activity
in an E-cadherin promoter-luciferase reporter gene assay (Fig- The downregulation of E-cadherin and increased -catenin-
TCF/LEF-1 transcriptional activities contribute to the develop-ure 4E). These data indicate that EGF-induced transcriptional
upregulation of Snail is necessary for downregulation of E-cadh- ment of invasive tumors. To examine whether the downregula-
tion of caveolin-1 induced by EGF plays a role in EGF-inducederin in 293T cells. Furthermore, luciferase assays with a Snail
promoter-luciferase reporter gene (Peinado et al., 2003) showed tumor cell invasion, an in vitro collagen gel analysis was carried
out. In contrast to the parental cells, which are flat and formthat EGF-induced expression of Snail is due to increased Snail
transcription (Figure 4F). Moreover, EGF-induced Snail tran- tight cell-cell contacts on the collagen gel surface, A431 cells
expressing antisense caveolin-1 RNA exhibited typical mesen-scription was blocked by expression of wild-type caveolin-1,
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Figure 4. Downregulation of caveolin-1 is suffi-
cient for the upregulation of Snail and the down-
regulation of E-cadherin
A: The expression of caveolin-1 (left panel),
E-cadherin (middle panel), and ERK1/2 (right
panel) in A431 cells (upper panel) and A431 cells
expressing antisense caveolin-1 RNA (lower
panel) treated with or without EGF (100 ng/ml)
for the indicated times were analyzed by SDS-
PAGE and immunoblotting with the indicated
antibodies.
B: The mRNA levels of E-cadherin (upper panel),
-catenin (middle panel), and -actin (lower
panel) in A431 cells or A431 cells expressing anti-
sense caveolin-1 RNA were analyzed by North-
ern blotting.
C: Snail mRNA expression was measured by RT-
PCR analyses from A431 cells treated or un-
treated with EGF or expressing the antisense ca-
veolin-1 construct. -actin mRNAs from the same
cDNA were amplified as a control.
D: RT-PCR analyses were carried out for mRNA
expression of Snail and -actin in 293T cells trans-
fected with pRS or pRS-Snail.
E: pRS or pRS-Snail plasmids with pEGFR and pGL
3-E-cad were transiently transfected into 293T
cells. Cells were either left untreated or treated
with EGF (100 ng/ml) for 12 hr before harvesting.
Cell extracts were processed for measuring lucif-
erase activity. Data represent the mean 	 stan-
dard deviation of 3 independent experiments.
F: pEGFR and pLuc-Snail were transfected into
293T cells with or without plasmids expressing
wild-type caveolin-1 or antisense caveolin-1. Lu-
ciferase activities were determined after cells
were treated with or without EGF (100 ng/ml) for
12 hr.
chymal morphology and loss of cell-cell adhesions (Figure 7A, process involving changes in cell-ECM and cell-cell junctions.
Although E-cadherin downregulation also correlates with tumorleft panels). Seven days after seeding, a larger number of A431
cells expressing antisense caveolin-1 RNA were able to pene- development, whether there is a connection between EGFR
overexpression and E-cadherin downregulation is not known,trate into collagen gel in the absence of EGF treatment com-
pared to the parental cells (Figure 7A, middle panels). EGF nor is the mechanism by which EGF affects cell-cell contacts.
Here we demonstrate that EGF treatment of human tumor cellstreatment (100 ng/ml), which caused further downregulation of
caveolin-1 and E-cadherin in antisense caveolin-1-expressing that overexpress EGFR results in the disruption of cell-cell con-
tacts by two distinct mechanisms: internalization of bothcells, enhanced the invasiveness of A431 cells expressing anti-
sense caveolin-1 RNA compared to parental cells treated with E-cadherin and -catenin induced at early times of EGF treat-
EGF (Figures 7A, right panels, and 7B). These data indicate that ment and depletion of E-cadherin upon prolonged EGF treat-
the downregulation of caveolin-1 plays an important role in EGF- ment (Figure 8). Importantly, EGF-dependent regulation of ca-
induced tumor cell invasion. veolin-1 plays a critical role in both processes. Our studies were
restricted to examining the effect of EGF on tumor cell lines,
and it will be interesting to ask whether these processes areDiscussion
restricted to metastasis and the invasive phase of tumor pro-
gression or whether this mechanism is also utilized during nor-EGFR overexpression correlates with tumor progression, me-
tastasis, and poor clinical prognosis. Metastasis is a complex mal development and/or differentiation of epithelia. In this re-
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Figure 5. Downregulation of caveolin-1 is neces-
sary and sufficient for EGF-induced -catenin
transcriptional activity
FOP-FLASH or TOP-FLASH plasmids with pEGFR
were transiently transfected with vectors ex-
pressing antisense or wild-type caveolin-1 into
293T cells. Cells were either left untreated or
treated with EGF (100 ng/ml) for 12 hr before
harvesting. Cell extracts were processed for
measurement of luciferase activity. Data repre-
sent the mean 	 standard deviation of 3 inde-
pendent experiments.
gard, a recent report indicates that EGF treatment of normal by internalization of E-cadherin. Moreover, caveolin-1, the prin-
Madin-Darby canine kidney (MDCK) cells results in increased ciple constituent of caveolae, relocalized into endosomal com-
tight junction function through downregulation of claudin-2 and partments that partially overlapped the Golgi, consistent with
upregulation of claudins-1 and 3, without an effect on E-cadh- the observations of Pol et al. (2000). Structural disruption of
erin levels (Singh and Harris, 2003). caveolae by cholesterol depletion with filipin or -cyclodextrin,
The abundance and function of cell-surface molecules can which inhibits caveolar function and blocks caveolae-mediated
be dynamically regulated by endocytosis. We demonstrated endocytosis (Ros-Baro et al., 2001; Torgersen et al., 2001),
that EGF treatment of human tumor cells overexpressing EGFR resulted in the retention of both caveolin-1 and E-cadherin at
caused a dramatic alteration in cell-cell contacts accompanied the cell surface. These results suggest that caveolin-1 might play
an important role in the endocytosis of E-cadherin. However, we
cannot rule out the possibility that E-cadherin internalization is
mediated by a caveolin-independent endocytotic pathway that
is directly or indirectly disrupted by cholesterol depletion. Ca-
veolar vesicles transport many macromolecules to the endo-
plasmic reticulum, the Golgi apparatus, or across the cell (trans-
cytosis) (Shin and Abraham, 2001), but this does not lead to
lysosomal degradation of proteins. Consistent with this, there
was little effect of EGF treatment on the half-life of E-cadherin,
and this suggests that EGF-induced internalization of E-cadh-
erin plays a role in the redistribution but not downregulation of
E-cadherin. The internalized E-cadherin returns to cell surface
and concomitantly cell-cell contacts are reestablished after re-
moval of EGF during transient treatments (data not shown).
Thus, clathrin-independent E-cadherin endocytosis and disso-
ciation of E-cadherin/-catenin complexes during the early
stages of EGF treatment serve to disrupt cell-cell contacts by
removal of major adherens components from the cell surface.
In contrast to the constitutive clathrin-mediated endocytic
pathway, caveolae are normally immobile plasma membrane
domains kept in place by the actin cytoskeleton under unstimu-
lated conditions, and there is a very limited exchange of caveo-
lin-1 with the intracellular pool (Lippincott-Schwartz et al., 2001;
Figure 6. The effects of EGF autocrine regulation on cell morphology and Thomsen et al., 2002). Much like caveolin-1, only a small fraction
the expression levels of caveolin-1 and E-cadherin of E-cadherin, likely that present in the extrajunctional regions
A431 cells were grown in the absence or presence of AG1478 (300 nM) for of the lateral surface rather than the adherens junctions, recycles
7 days. The morphology of the cells (A) and the expression levels of caveo-
in stable epithelial monolayers of MDCK cells, possibly throughlin-1, E-cadherin, and FAK (B) as assessed by immunoblotting were exam-
ined as described in Figure 1. the clathrin-dependent pathway (Le et al., 1999). The pool of
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Figure 7. Downregulation of caveolin-1 is sufficient for EGF-induced cell invasion
A431 cells and A431 cells expressing antisense caveolin-1 RNA were plated on the top of collagen gel, and EGF (100 ng/ml) was added to the medium
1 day later.
A: Seven days after plating, cells were photographed either at the top surface of gel (left panels) or at a focal plane beneath the surface to visualize
cells that have penetrated the gel (middle and right panels).
B: The numbers of invading cells in 10 photographic fields from 3 separate experiments were counted. Data represent the mean 	 standard deviation of
3 independent experiments.
E-cadherin undergoing endocytosis and recycling is dramati- nantly endocytosed by clathrin-independent and dynamin-
dependent endocytosis in which ARF6 activity is involved (Pat-cally increased in cells without stable cell-cell contacts (Le et al.,
1999). Various stimuli can lead to internalization of E-cadherin. erson et al., 2003). In HGF-treated MDCK cells, ARF6 is required
for clathrin/dynamin-dependent endocytosis of E-cadherin (Pa-Expression of constitutively active Rac1 results in disruption of
cell-cell contacts and endocytosis of E-cadherin via a clathrin- lacios et al., 2002). Moreover, an ARF6-dependent initial de-
crease in the level of Rac1 GTP appears to be necessary forindependent but possibly a caveolae-mediated pathway (Akhtar
and Hotchin, 2001). However, other processes that may not v-Src-induced cell-cell dissociation (Palacios and D’Souza-
Schorey, 2003). These data suggests that E-cadherin can beinvolve caveolae-dependent internalization also regulate endo-
cytosis of E-cadherin. For instance, when E-cadherin is free on internalized by multiple pathways in different cellular contexts.
We demonstrated that caveolin-1 and E-cadherin interactthe plasma membrane of isolated MCF-7 cells, it is predomi-
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and colocalize at cell-cell contacts. Upon EGF treatment, cell- term treatment with EGF, and loss of caveolin-1 results in tran-
scriptional downregulation of E-cadherin during long-term EGFcell contacts were disrupted, accompanied by a dramatic mor-
phological change. While the exact role of caveolin-1 in E-cadh- treatment (Figure 8).
EGF-induced downregulation of E-cadherin transcriptionerin endocytosis is not clear, it was recently shown that when
E-cadherin is tyrosine phosphorylated by Src, it recruits Hakai, appears to involve upregulation of Snail, but the mechanism
through which Snail is upregulated by EGF is unclear. Our dataa c-Cbl-like ubiquitin E3 ligase, which in turn ubiquitylates
E-cadherin (Fujita et al., 2002). This may induce the endocytosis indicate that E-cadherin gene expression is dependent on the
presence of caveolin-1 and possibly intact caveolae. Many sig-of E-cadherin. Moreover, a role for small G proteins in HGF-
induced endocytosis of E-cadherin in MDCK cells has also been naling molecules such as EGFR, PDGFR, Neu/ErbB2, Ha-Ras,
c-Src, and PI-3-kinase localize in caveolae and are negativelysuggested (Kamei et al., 1999; Palacios et al., 2001). In response
to EGF treatment, we found that caveolin-1 was tyrosine phos- regulated through their interaction with caveolin-1 (Okamoto et
al., 1998). Thus, downregulation of caveolin-1 from caveolaephorylated and monoubiquitylated, although we did not detect
any change in the phosphorylation of E-cadherin (data not through internalization at early times of EGF treatment and re-
duced expression through prolonged EGF treatment or anti-shown). We speculate that tyrosine-phosphorylated caveolin-1,
or EGFR, which also localizes at caveolae, recruits an SH2 sense regulation of its mRNA could in principle result in the
release of signaling proteins from caveolae that then upregulatedomain containing E3 ligase, such as c-Cbl or Hakai, which in
turn ubiquitylates caveolin-1. Monoubiquitylation has attracted transcription of the Snail gene and thereby indirectly reduce
E-cadherin gene transcription. The resultant depletion of E-cadh-considerable attention as a mechanism for targeting receptor
molecules for endocytosis (Hicke, 2001). Additionally, some of erin could prevent cells from reforming cell-cell contacts and
facilitate EMT, possibly in combination with increased signalingthe components of clathrin-dependent endocytosis machinery,
such as Eps15 and Eps15R (which are themselves monoubiqui- due to loss of caveolin-1 and with enhanced -catenin-TCF/
LEF-1-mediated transcription due to release and nuclear importtylated), epsins, and Vps27p, have a ubiquitin binding domain
(Polo et al., 2002; Shih et al., 2002). Therefore, it is tempting to of -catenin.
Caveolin-1 expression is reduced in lung cancer, colon can-speculate that either ubiquitylation of caveolin-1 itself or associ-
ation of monoubiquitylated adaptor proteins may play an analo- cer, ovarian cancer, and sarcoma (Bagnoli et al., 2000; Bender
et al., 2000; Racine et al., 1999; Razani et al., 2001b; Wiechengous role in the clathrin-independent endocytosis of caveolin-1
and possibly of caveolin-1-associated E-cadherin. et al., 2001). Moreover, a common sporadic caveolin-1 mutation
has been found in human breast cancer (Hayashi et al., 2001;In contrast to the effects of transient stimulation with EGF,
chronic treatment resulted in reduced expression of caveolin-1 Lee et al., 2002). Reduced expression of caveolin-1 correlates
with poor tumor prognosis. In addition, overexpressed cav-and E-cadherin proteins due to downregulation of their mRNA
levels. Interestingly, ERK1/2 MAP kinase signaling, an important eolin-1 reduced transforming phenotypes of lung and breast
cancer cells, supporting an inhibitory role of caveolin-1 in tumortarget of EGFR activation, downregulates caveolin-1 transcrip-
tion (Engelman et al., 1999). It has also been reported that progression (Lee et al., 1998; Racine et al., 1999). Paradoxically,
caveolin-1 expression is increased in prostate cancer andtreatment of human lung cancer cell lines with a ligand-blocking
monoclonal antibody against EGFR results in increased expres- esophageal cancer, suggesting a positive role in tumor develop-
ment (Kato et al., 2002; Li et al., 2001; Mouraviev et al., 2002).sion of E-cadherin (Al Moustafa et al., 1999, 2002). We found
that interruption of EGF autocrine signaling in A431 epidermoid These data imply that caveolin-1 has multifunctional activities
in cancer dependent on interacting signal molecules and thecarcinoma cells with the EGFR inhibitor AG1478 increased ex-
pression of E-cadherin and caveolin-1, accompanied by normal specific cell type/tissue context. Caveolin-1 is reported to inter-
act with the androgen and estrogen receptors and potentiateepithelial-like phenotypic change. The suppression of caveo-
lin-1 and E-cadherin promoter activity by EGF indicates that their transcriptional activity (Lu et al., 2001a; Razandi et al.,
2003; Schlegel et al., 1999), and this may contribute to thetheir transcription is downregulated. Depletion of caveolin-1 by
antisense RNA expression recapitulated the effect of EGF and growth of sex hormone-related tumors.
Upregulation of -catenin transcriptional activity has beendownregulated E-cadherin expression, indicating that downreg-
ulation of caveolin-1 is sufficient for downregulation of E-cadh- observed in several types of cancers, such as colon cancer,
melanoma, and prostate cancer (Morin, 1999; Peifer and Po-erin. Consistent with this, antisense RNA-mediated depletion
of caveolin-1, which mimics the effects of EGF treatment, re- lakis, 2000). We found that EGF treatment resulted in dissocia-
tion of -catenin from E-cadherin, internalization from cell-cellsulted in the increased expression of Snail, a transcriptional
regulator that directly represses E-cadherin promoter activity contacts, increased nuclear localization, and stimulation of
-catenin-TCF/LEF-1 transcriptional activity. The internalizationand induces EMT (Batlle et al., 2000; Cano et al., 2000). More-
over, EGF-induced upregulation of Snail transcription is depen- and depletion of both caveolin-1 and E-cadherin destabilizes
the E-cadherin and -catenin complex and allows translocationdent on downregulation of caveolin-1. Thus, while E-cadherin
is functionally inactivated by a caveolin-1-dependent internal- of -catenin from the cell membrane to the nucleus. Consistent
with this, overexpression of caveolin-1, which recruits -cateninization mechanism during transient EGF treatment, long-term
EGF treatment causes downregulation of caveolin-1, leading to to caveolar membranes (Galbiati et al., 2000), blocks EGF-
induced-catenin-mediated transactivation, which is in line withtranscriptional repression of E-cadherin through induction of
Snail, and thus accounts for loss of E-cadherin during long- transcriptional repression of cyclin D1 gene by caveolin-1, which
is dependent on the TCF/LEF-1 binding site in the cyclin D1term EGF treatment. Therefore, caveolin-1 may play two distinct
roles in EGF regulation of E-cadherin function and loss of cell- promoter (Hulit et al., 2000). These results indicate that
caveolin-1 plays an essential role in regulation of -catenincell contacts: caveolin-1 may directly or indirectly participate in
removal of E-cadherin from the plasma membrane during short- transcriptional activity. -catenin-TCF/LEF-1-dependent tran-
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Figure 8. Disruption of cell-cell adhesion junction and -catenin/TCF/LEF-1 transactivation
Left: Early phase of EGF treatment: caveolae-mediated E-cadherin endocytosis and dissociation of E-cadherin/-catenin complexes during the early stages
of EGF treatment serve to disrupt junctions by removal of these adherens components from cell surface. Release of signaling molecules sequestered by
caveolin-1, which may also contribute to the activation of -catenin, turn on the transcriptional machinery and suppress the transcription of caveolin-1
and E-cadherin.
Right: Late phase of EGF treatment: reduced expression of E-cadherin protein due to suppression of E-cadherin promoter activity and downregulation of
its mRNA level through EGF-induced upregulation of Snail prevents cells from reforming cell-cell junctions and facilitates EMT.
scription can be positively regulated by both PKB/AKT-medi- overexpressing tumor cells function as signals to direct the
ated phosphorylation and inactivation of GSK-3 (Weston and disruption of cell adhesion to ECM mediated through dephos-
Davis, 2001). We did not detect reduced-catenin phosphoryla- phorylation and inactivation of FAK (Lu et al., 2001b). Moreover,
tion at the GSK-3 sites, increased phosphorylation of GSK- it also directs the disruption of cell-cell contacts and causes
3 itself at the site that inhibits its kinase activity, or any apparent EMT through caveolin-1-mediated internalization and transcrip-
change of half-life of -catenin in response to EGF treatment tional downregulation of E-cadherin. Induction of protoonco-
(data not shown). Thus, it is unlikely that EGF-induced -catenin- genes, such as c-myc and cyclin D1, through a GSK-3-inde-
TCF/LEF-1 transcriptional activity is due to negative regulation pendent increase in -catenin-TCF/LEF-1 transcriptional activity
of GSK-3, which leads to stabilization of -catenin complexed provides a further drive for progression to an invasive stage
with APC-axin. EGF-induced -catenin transactivation may be of tumor development. Our studies reveal that the phenotypic
potentiated by posttranslational modification of -catenin itself effects of EGF, internalization and transcriptional downregula-
or of a -catenin binding coactivator. Although the nature of
tion of E-cadherin, and increased transactivation by -catenin
this activation is not clear, our results suggest that the internal-
are all mediated through downregulation of caveolin-1, whichization and depletion of caveolin-1 leads to release of inhibited
represents a novel and important mechanism underlying thesignaling molecules normally sequestered in caveolae, which
effects of EGF during tumor development. The demonstrationin turn contribute to -catenin transactivation. We conclude that
of an interplay between EGF and Wnt/Wingless signaling com--catenin-TCF/LEF-1 transcriptional activity can be regulated
ponents provides an important insight for further understandingthrough at least two distinct mechanisms: GSK-3-dependent
tumor cell invasion and metastasis.regulation mediated by Wnt/Wingless signaling and PKB/AKT-
and GSK-3-independent regulation mediated though EGF sig-
Experimental proceduresnaling by the regulation of caveolin-1.
The downregulation of E-cadherin, increased -catenin-
Cells and cell culture conditionsTCF/LEF-1 transcriptional activity, and EGFR overexpression
A431 human epidermoid carcinoma cells, DU145 prostate cells, A549 human
and EGF-induced signaling have all been separately reported non-small cell lung cancer cells, NBT-II rat bladder carcinoma cells, and
to correlate with an invasive stage of tumor development. Here 293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
we provide a mechanistic model for tumor cell invasion and supplemented with 10% fetal bovine serum (HyClone). Cell cultures were
metastasis that integrates these different components. EGF made quiescent by growing them to confluence and then replacing the
medium with fresh medium containing 0.5% serum for 1 day.family members secreted during autocrine regulation of EGFR-
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Materials Luciferase reporter gene assay
In order to measure the transcriptional activity of TCF/LEF-1, 293T cellsPolyclonal antibodies for ERK1 (K-23), FAK, PCNA, c-Myc, caveolin-1 (N20),
were seeded in 12-well plates at 3 
 103 cells/well. 24 hr after seeding,vimentin, E-cadherin (H108), and monoclonal antibody for -catenin (E-5)
cells were transiently transfected with 0.5 g of pEGFR, 0.5 g TCF/LEF-1and cytokeratin were from Santa Cruz Biotechnology. Anti-caveolin-1 mono-
reporter (pTOP-FLASH), or control vector (pFOP-FLASH) with or without 0.5clonal antibody (C37120) was obtained from Transduction Laboratories, and
g wild-type caveolin-1 or antisense-caveolin-1 expression vector. Twelvethe 4G10 anti-phosphotyrosine monoclonal antibody from Upstate Biotech-
hours after transfection, the medium was replaced with 0.1% serum fornology. Polyclonal phospho--catenin (Ser33/Ser37/Thr41)-specific anti-
another 24–36 hr, and EGF (100 ng/ml) was added 6 hr before harvesting.bodies were from Cell Signaling Technology. Monoclonal antibody for ZO-1
Ten microliters out of the 100 l cell extract were used for measuring lucifer-was from Zymed laboratories. Polyclonal antibody against -COP was from
ase activity. pA3Luc-caveolin-1, pGL 3-E-cad (178/92) vector, or pLuc-Affinity Bioreagents. Human EGF, filipin, methyl--cyclodextrin, TRITC-
Snail was transfected as described above to measure the promoter activitylabeled phalloidin, monoclonal -tubulin antibody, and FITC-conjugated al-
of caveolin-1, E-cadherin, or Snail, respectively.bumin were purchased from Sigma. Hygromycin was from GIBCO. AG1478
and calyculin A were obtained from Calbiochem. FITC-conjugated anti-
Pulse-chase analysismouse antibody and Texas red-conjugated anti-rabbit antibody were from
A431 cells treated or untreated with EGF (100 ng/ml) for 3 days were incu-Southern Biotechnology Associates. Cy-5-conjugated anti-mouse antibody,
bated in the absence of methionine for 20 min, pulse-labeled for 1 hr with 250Hoechst 33342, and Alexa Fluor 594 conjugated transferrin were from Molec-
Ci/ml [35S] methionine, washed twice, and incubated in medium containingular Probes. To generate the pRETRO-SUPER-Snail (pRS-Snail), the pRE-
excess unlabeled methionine for 0, 2, 4, or 24 hr in the presence or absenceTRO-SUPER vector (pRS) (Brummelkamp et al., 2002) was digested with
of EGF (100 ng/ml). Proteins were immunoprecipitated with the indicatedBglII and HindIII, and the annealed oligonucleotides GATCCCCGATGC
antibodies. Samples were then separated on 6% SDS-polyacrylamide gelsACATCCGAAGCCACTTCAAGAGAGTGGCTTCGGATGTGCATCTTTTTG
and transferred to nitrocellulose membranes for exposure to X-ray film.GAAA and AGCTTTTCCAAAAAGATGCACATCCGAAGCCACTCTCTTGAA
GTGGCTTCGGATGTGCATCGGG were ligated into the vector.
Northern blot analysis
Total RNA was isolated from A431 cells using the RNeasy MiniKit (Qiagen,
Transfection Santa Clarita, CA) according to the manufacturer’s instructions. Aliquots (20
Cells were plated at a density of 4 
 104 per 60 mm diameter dish 18 hr
g) of total RNA were separated electrophoretically on 1.2% (w/v) agarose/
prior to transfection. Transfection was performed using either calcium phos- formaldehyde gels (equal loading was monitored by ethidium bromide stain-
phate or LipofectAmine reagent (GIBCO) according to the vendor’s instruc- ing of the gel), blotted on Hybond-N (Amersham) membranes, and hybrid-
tions. Transfected cultures were selected with hygromycin (200 g/ml) for ized with 32P-labeled cDNA probes, which were prepared by using Prime-
10 to 14 days at 37C. At that time antibiotic-resistant colonies were picked, It II Random Prime labeling Kit (Stratagene, La Jolla, CA) following the
pooled, and expanded for further analysis under selective conditions. manufacturer’s instructions. Subsequent washes were performed at 65C,
using standard procedures from Current Protocols in Molecular Biology.
Immunoprecipitation and immunoblotting analysis
Extraction of proteins from cultured cells was performed with a lysis buffer RT-PCR
consisting of 50 mM Tris-HCl (pH 7.5), 0.1% SDS, 1% Triton X-100, 150 First-strand cDNA from 2 g of total RNA was synthesized using ProStar
mM NaCl, 1 mM dithiothreitol, 0.5 mM EDTA, 0.1 mM phenylmethylsulfonyl First Strand RT-PCR Kit (Stratagene, Cedar Creek, TX). For Snail RNA ampli-
fluoride, leupeptin (12 mg/ml), aprotinin (20 mg/ml), 100 mM sodium vana- fication, the first round of PCR used 2 l of the cDNA and primers ATGCCG
date, 100 mM sodium pyrophosphate, and 1 mM sodium fluoride. Cell CGCTCCTTCCTGGTCAGG and TCAGCGAGGGCCTCCGGAGCAGCC. A
nested PCR was performed as described previously (Poser et al., 2001).extracts were clarified by centrifugation at 12,000 rpm, and the supernatants
-actin RNA amplification was carried out for 25 cycles using primers(1.5 mg protein/ml) were subjected to immunoprecipitation with the indicated
GTGGTGGTGAAGCTGTAGCC and GACGAGGCCCAGAGCAAGAGAGG.antibodies. After overnight incubation at 4C, protein A or G agarose beads
were added and left for an additional 3 hr. Immunocomplexes were washed
Acknowledgmentswith lysis buffer 3 times and then subjected to immunoblotting analysis as
described previously (Lu et al., 1998).
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